Loading news...
Updating on Strategic Progress and Outlook REHOVOT, Israel, Feb. 25, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries today issued a Letter to Shareholders from Ofer Haviv, President and Chief Executive Officer.
Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday , March 5 , 2026.
Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathways REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia.
The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the development of novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD).
REHOVOT, Israel and BOSTON, Feb. 10, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the August 2024 Series A ordinary warrants to purchase up to 1,692,308 ordinary shares (the "Series A Warrants"), and August 2024 Series B ordinary warrants to purchase up to 1,692,308 ordinary shares (the "Series B Warrants" and together with the Series A Warrants, the "Existing Warrants").
The new collaboration is expected to accelerate, scale and advance small-molecule discovery and optimization for pharmaceutical and agricultural products REHOVOT, Israel, Feb. 10, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for the pharmaceutical and agricultural industries, today announced an expanded phase of its collaboration with Google Cloud.
Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AI™ for Drug and Ag-Chemical Discovery REHOVOT, Israel, Feb. 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the AI-driven discovery and design of novel small molecules for the pharmaceutical and agricultural industries, today announced the appointment of Prof.
BMC128 was developed by Biomica, Evogene's subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results BMC128 was developed by Biomica, Evogene's subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results
BMC128 was developed by Biomica, Evogene's subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results REHOVOT, Israel and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biopharmaceuticals Co., Ltd.
Evogene Ltd. (NASDAQ: EVGN - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.19 and traded as low as $1.03. Evogene shares last traded at $1.0550, with a volume of 31,891 shares. Analyst Upgrades and Downgrades Separately, Weiss Ratings restated a
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF) is pleased to announce that the new 20-year Biomethane Purchase Agreement previously entered into between FortisBC Energy Inc. (“FortisBC”) and EverGen's wholly owned subsidiary, Fraser Valley Biogas Ltd. (“FVB”), for Renewable Natural Gas (“RNG”) produced at the FVB facility (the “BPA”) is now in effect. Under the BPA, FortisBC will purchase RNG from FVB for inclu.
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or “the Company”) (TSXV: EVGN) (OTCQB: EVGIF), is pleased to announce the closing of its previously announced $13.0 million asset-level debt facility with Farm Credit Canada (“FCC”) through its wholly owned subsidiary Fraser Valley Biogas Ltd. (“FVB”), the repayment of the majority of the Company's corporate debt facility, and the closing of the second tranche of its previously announced non-brokered private p.
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or “the Company”) (TSXV: EVGN) (OTCQB: EVGIF), is pleased to provide an update on the Company's debt refinancing activities and private placement. As previously announced in May 2025, EverGen had executed a letter of intent for a $13 million asset level debt facility, proceeds of which would be used to repay a majority of its corporate debt, with terms that are better aligned with the Company's current operati.
Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design and patient-derived predictive platform REHOVOT, Israel and BOSTON, January 7, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform.
Evogene Ltd. (NASDAQ: EVGN - Get Free Report) shares passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $1.12 and traded as low as $1.12. Evogene shares last traded at $1.12, with a volume of 23,987 shares changing hands. Analyst Ratings Changes Separately, Weiss
REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026.
EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
EverGen Infrastructure Corp. ( EVGN:CA ) Q3 2025 Earnings Call November 21, 2025 11:00 AM EST Company Participants Chase Edgelow - CEO & Director Maria O'Sullivan - Interim Chief Financial Officer Presentation Operator Welcome to the EverGen Infrastructure Third Quarter 2025 earnings results presentation. [Operator Instructions] As a reminder, this call is being recorded.
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q3 2025. All amounts are in Canadian dollars unless otherwise stated and have been prepared in accordance with IFRS. RNG production: reached a new quarterly record in Q3 2025, following the stabilization of the FVB RNG expansion project. During July, August and September 2025, the FVB and GrowTEC facilities collective.
Evogene Ltd. ( EVGN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Ofer Haviv - CEO, President & Director Yaron Eldad - Chief Financial Officer Presentation Operator Welcome to Evogene's Third Quarter 2025 Results Conference Call.